Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

According to a study published in the National Center for Biotechnology Information, the prevalence of macular edema is anywhere from 4.2% to 7.9% in patients with type 1 diabetes and 1.4% to 12.8% in ...

Patient inclusion criteria were age 18 years or older, diagnosed with macular edema secondary to RVO in the study eye, received at least 2 injections of DEX implant 0.7 mg in the study eye ...

Focal grid macular laser surgery ... With proper treatment, many people with diabetic macular edema can preserve their vision. To learn more, visit webmd.com.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Dr. Sayed has has worked on more claims relating to Diabetic Retinopathy, Diabetic Macular Edema (DME) and Focal Chorioretinitis and Focal Retinochoroiditis than other providers in the area.

Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when high blood sugar levels damage small blood vessels in the retina, the light-sensitive tissue ...

We evaluated the efficacy and safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naïve patients. Methods: A multicenter, retrospective ...